Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes

Table 2

Changes in parameters for 3 months.

	Before	1 month	3 months
HbA1c (%)	8.56±1.5	8.13±1.26^∗∗	7.88±1.25^∗∗†
Body weight (kg)	63.3±12.9	63.2±12.9	63.5±12.9
Insulin dose (U/day)	29±18.6	27.7±18.8^∗∗	27.4±18.9^∗∗#
Within-day glucose variability (%)^a	24±10.7	22.7±10.3	22.6±11.4
Day-to-day glucose variability (%)^a	18.3±9.1	16.8±8.4^∗	16.1±8.1^∗

Abbreviations are shown in text. Repeated measures ANOVA with Bonferroni test.
Data are expressed as means ± S.D. ^a𝑛=115.
^∗𝑃<0.05, ^∗∗𝑃<0.001 versus before the initiation of sitagliptin.
^#𝑃<0.05, ^†𝑃<0.001 versus 1 month after the initiation of sitagliptin.